Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00790868 · ClinicalTrials.gov registry record · Phase 2
Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder
A Phase 2 study of Panic Disorder, sponsored by Boston University Charles River Campus.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 4
- Study locations
NCT00790868 is a Phase 2 study of Panic Disorder that has completed, run by Boston University Charles River Campus. The registered enrollment target is 180 participants, below the 215-participant average among 25 other Panic Disorder trials with a reported enrollment target (16% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT00790868, a Phase 2 study of Panic Disorder, has completed, sponsored by Boston University Charles River Campus.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a 5-year double blind, randomized, controlled, trial conducted at three treatment sites, aimed at showing the acute and longer-term effects of DCS augmentation of exposure-based CBT for panic disorder relative to placebo augmentation. By demonstrating that DCS can enhance the results of even a brief treatment strategy, the investigators are seeking to validate an approach that fits well with the practice limitations and applications of CBT in effectiveness studies.
Conditions Studied
Interventions
- DRUG placebo
- DRUG d-cycloserine
Study Locations (4)
Massachusetts
- Massachusetts General Hospital - Boston
- Boston University - Boston
Connecticut
- Institute of Living - Hartford
Illinois
- Rush University Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2008-04 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00790868
The ClinicalTrials.gov registry entry for NCT00790868 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 215-participant average among 25 other Panic Disorder trials with a reported enrollment target (16% lower). The listed sponsor is Boston University Charles River Campus, which has 104 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Panic Disorder appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00790868 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Connecticut, Illinois.
Frequently Asked Questions
What is clinical trial NCT00790868 about?
NCT00790868 is a clinical study titled "Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder". This is a 5-year double blind, randomized, controlled, trial conducted at three treatment sites, aimed at showing the acute and longer-term effects of DCS augmentation of exposure-based CBT for panic disorder relative to placebo augmentation. By demonstrating that DCS can enhance the results of even...
What is the current status of trial NCT00790868?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2008-04. Estimated completion is 2014-08.
What conditions does trial NCT00790868 study?
This clinical trial studies the following conditions: Panic Disorder.
What interventions are being tested in trial NCT00790868?
The interventions under investigation include: placebo (DRUG), d-cycloserine (DRUG).
Who is sponsoring clinical trial NCT00790868?
This trial is sponsored by Boston University Charles River Campus, which has 104 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00790868 being conducted?
This trial has 4 study locations across Connecticut, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Panic Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effectiveness of Cognitive Behavioral Therapy With Panic Control Treatment for Adolescents With Panic Disorder
COMPLETED · Phase 2
-
Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Panic Disorder With Comorbid Major Depression
COMPLETED · Phase 2
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
-
Neurofeedback Enhanced Cognitive Reappraisal Training - Phase 4
RECRUITING · NA
-
CO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy
RECRUITING · NA
-
Mindful Self-compassion for Anxiety and Depression: Impact of Delivery Method
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.